Literature DB >> 17710450

Matrix metalloproteinase-inhibitor interaction: the solution structure of the catalytic domain of human matrix metalloproteinase-3 with different inhibitors.

Luis A Alcaraz1, Lucia Banci, Ivano Bertini, Francesca Cantini, Antonio Donaire, Leonardo Gonnelli.   

Abstract

We structurally characterized the adducts of the catalytic domain of matrix metalloproteinase-3 (MMP3) with three different nonpeptidic inhibitors by solving the solution structure of one adduct [MMP3-N-isobutyl-N-(4-methoxyphenylsulfonyl)glycyl hydroxamic acid] and then by calculating structural models of the other two adducts using a reduced set of experimental NMR data, following a recently proposed procedure (Bertini et al. in J. Med. Chem. 48:7544-7559, 2005). The inhibitors were selected with the criteria of maintaining in all of them the same zinc-coordinating moiety and of selectively changing the substituents and/or the functional groups. The backbone dynamics on various time scales have been characterized as well. The comparison among these structures and with others previously reported allowed us to elucidate fine details of inhibitor-receptor interactions and to develop some criteria, which could guide in optimizing the design of selective inhibitors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17710450     DOI: 10.1007/s00775-007-0288-9

Source DB:  PubMed          Journal:  J Biol Inorg Chem        ISSN: 0949-8257            Impact factor:   3.358


  36 in total

1.  Design and therapeutic application of matrix metalloproteinase inhibitors.

Authors:  M Whittaker; C D Floyd; P Brown; A J Gearing
Journal:  Chem Rev       Date:  1999-09-08       Impact factor: 60.622

2.  The Xplor-NIH NMR molecular structure determination package.

Authors:  Charles D Schwieters; John J Kuszewski; Nico Tjandra; G Marius Clore
Journal:  J Magn Reson       Date:  2003-01       Impact factor: 2.229

3.  Automated NMR structure calculation with CYANA.

Authors:  Peter Güntert
Journal:  Methods Mol Biol       Date:  2004

4.  WHAT IF: a molecular modeling and drug design program.

Authors:  G Vriend
Journal:  J Mol Graph       Date:  1990-03

5.  Design, synthesis, and biological evaluation of matrix metalloproteinase inhibitors derived from a modified proline scaffold.

Authors:  M Cheng; B De; N G Almstead; S Pikul; M E Dowty; C R Dietsch; C M Dunaway; F Gu; L C Hsieh; M J Janusz; Y O Taiwo; M G Natchus; T Hudlicky; M Mandel
Journal:  J Med Chem       Date:  1999-12-30       Impact factor: 7.446

6.  Combining in silico tools and NMR data to validate protein-ligand structural models: application to matrix metalloproteinases.

Authors:  Ivano Bertini; Marco Fragai; Andrea Giachetti; Claudio Luchinat; Massimiliano Maletta; Giacomo Parigi; Kwon Joo Yeo
Journal:  J Med Chem       Date:  2005-12-01       Impact factor: 7.446

7.  Crystal structure of the stromelysin catalytic domain at 2.0 A resolution: inhibitor-induced conformational changes.

Authors:  L Chen; T J Rydel; F Gu; C M Dunaway; S Pikul; K M Dunham; B L Barnett
Journal:  J Mol Biol       Date:  1999-10-29       Impact factor: 5.469

8.  Identification by NMR of the binding surface for the histidine-containing phosphocarrier protein HPr on the N-terminal domain of enzyme I of the Escherichia coli phosphotransferase system.

Authors:  D S Garrett; Y J Seok; A Peterkofsky; G M Clore; A M Gronenborn
Journal:  Biochemistry       Date:  1997-04-15       Impact factor: 3.162

9.  Crystal structure of the catalytic domain of human matrix metalloproteinase 10.

Authors:  I Bertini; V Calderone; M Fragai; C Luchinat; S Mangani; B Terni
Journal:  J Mol Biol       Date:  2004-02-20       Impact factor: 5.469

Review 10.  The design, structure, and clinical update of small molecular weight matrix metalloproteinase inhibitors.

Authors:  Jerry W Skiles; Nina C Gonnella; Arco Y Jeng
Journal:  Curr Med Chem       Date:  2004-11       Impact factor: 4.530

View more
  8 in total

1.  A multidisciplinary approach to probing enthalpy-entropy compensation and the interfacial mobility model.

Authors:  Erin M Wilfong; Yuri Kogiso; Sivaramakrishnan Muthukrishnan; Thomas Kowatz; Yu Du; Amber Bowie; James H Naismith; Christopher M Hadad; Eric J Toone; Terry L Gustafson
Journal:  J Am Chem Soc       Date:  2011-07-07       Impact factor: 15.419

2.  A macrophage cell model for selective metalloproteinase inhibitor design.

Authors:  Faith E Jacobsen; Matthew W Buczynski; Edward A Dennis; Seth M Cohen
Journal:  Chembiochem       Date:  2008-09-01       Impact factor: 3.164

3.  Overexpressed C-type natriuretic peptide serves as an early compensatory response to counteract extracellular matrix remodeling in unilateral ureteral obstruction rats.

Authors:  Peng Hu; Jing Wang; Xue Qi Zhao; Bo Hu; Ling Lu; Yuan Han Qin
Journal:  Mol Biol Rep       Date:  2012-10-17       Impact factor: 2.316

4.  Inhibiting Matrix Metalloproteinase 3 Ameliorates Neuronal Loss in the Ganglion Cell Layer of Rats in Retinal Ischemia/Reperfusion.

Authors:  Tu Hu; Qiuting You; Dan Chen; Jianbin Tong; Lei Shang; Jia Luo; Yi Qiu; Huimin Yu; Leping Zeng; Jufang Huang
Journal:  Neurochem Res       Date:  2016-01-30       Impact factor: 3.996

Review 5.  Rational approaches to improving selectivity in drug design.

Authors:  David J Huggins; Woody Sherman; Bruce Tidor
Journal:  J Med Chem       Date:  2012-01-12       Impact factor: 7.446

6.  Metabolic Response of Human Osteoarthritic Cartilage to Biochemically Characterized Collagen Hydrolysates.

Authors:  Saskia Schadow; Viktor S Simons; Guenter Lochnit; Jens Kordelle; Zuzana Gazova; Hans-Christian Siebert; Juergen Steinmeyer
Journal:  Int J Mol Sci       Date:  2017-01-20       Impact factor: 5.923

7.  Mechanistic Insights into Biological Activities of Polyphenolic Compounds from Rosemary Obtained by Inverse Molecular Docking.

Authors:  Samo Lešnik; Urban Bren
Journal:  Foods       Date:  2021-12-28

8.  Efficacy of Chondroprotective Food Supplements Based on Collagen Hydrolysate and Compounds Isolated from Marine Organisms.

Authors:  Thomas Eckert; Mahena Jährling-Butkus; Helen Louton; Monika Burg-Roderfeld; Ruiyan Zhang; Ning Zhang; Karsten Hesse; Athanasios K Petridis; Tibor Kožár; Jürgen Steinmeyer; Roland Schauer; Peter Engelhard; Anna Kozarova; John W Hudson; Hans-Christian Siebert
Journal:  Mar Drugs       Date:  2021-09-26       Impact factor: 5.118

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.